NO20005913D0 - Legemiddelsammensetning - Google Patents
LegemiddelsammensetningInfo
- Publication number
- NO20005913D0 NO20005913D0 NO20005913A NO20005913A NO20005913D0 NO 20005913 D0 NO20005913 D0 NO 20005913D0 NO 20005913 A NO20005913 A NO 20005913A NO 20005913 A NO20005913 A NO 20005913A NO 20005913 D0 NO20005913 D0 NO 20005913D0
- Authority
- NO
- Norway
- Prior art keywords
- medicinal composition
- medicinal
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14091598 | 1998-05-22 | ||
| PCT/JP1999/002681 WO1999061061A1 (fr) | 1998-05-22 | 1999-05-21 | Composites medicamenteux |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005913D0 true NO20005913D0 (no) | 2000-11-22 |
| NO20005913L NO20005913L (no) | 2001-01-22 |
Family
ID=15279786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005913A NO20005913L (no) | 1998-05-22 | 2000-11-22 | Legemiddelsammensetning |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6835807B1 (no) |
| EP (1) | EP1080732A4 (no) |
| JP (1) | JP4560210B2 (no) |
| KR (1) | KR100581443B1 (no) |
| CN (1) | CN1250293C (no) |
| AU (1) | AU3733399A (no) |
| CA (1) | CA2333321A1 (no) |
| EA (1) | EA003398B1 (no) |
| HK (1) | HK1040052B (no) |
| NO (1) | NO20005913L (no) |
| TW (1) | TWI253935B (no) |
| WO (1) | WO1999061061A1 (no) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| EP1619210A1 (en) * | 1998-10-30 | 2006-01-25 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
| CA2412582A1 (en) * | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Dds compound and process for the preparation thereof |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| JP4959136B2 (ja) * | 2002-12-13 | 2012-06-20 | イミューノメディクス、インコーポレイテッド | 細胞内で開裂可能な結合を有する免疫接合体 |
| US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
| AU2005216251B2 (en) * | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1973952A4 (en) * | 2006-01-23 | 2010-09-01 | Kwangju Inst Sci & Tech | CONJUGATE COMPRISING A COVALENT TO A MUCOADHESIVE POLYMER-ASSOCIATED PHARMACEUTICALLY ACTIVE COMPOUND, AND A TRANSMUCOSAL ADMINISTRATION METHOD FOR A PHARMACEUTICALLY ACTIVE COMPOUND USING THEREOF |
| CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
| WO2009130564A1 (en) * | 2008-04-22 | 2009-10-29 | Fidia Farmaceutici S.P.A. | Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias |
| SG184859A1 (en) | 2010-04-15 | 2012-11-29 | Spirogen Developments Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| CN103140512B (zh) | 2010-05-25 | 2017-03-01 | 辛德弗雷克斯公司 | 聚合物缀合的MetAP2抑制剂及其应用的治疗方法 |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
| CN104080811B (zh) | 2011-11-04 | 2019-09-27 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| AU2013328111B2 (en) | 2012-10-11 | 2017-11-02 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2906251B1 (en) | 2012-10-12 | 2017-09-27 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| PL2906298T3 (pl) | 2012-10-12 | 2019-04-30 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina - przeciwciało |
| EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| MX364326B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina - anti-psma. |
| TR201808051T4 (tr) | 2012-10-12 | 2018-06-21 | Adc Therapeutics Sa | Pirrolobenzodiazepin antikor konjugatları. |
| ES2738310T3 (es) | 2012-10-12 | 2020-01-21 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
| WO2014061277A1 (ja) * | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| WO2014096365A1 (en) | 2012-12-21 | 2014-06-26 | Spirogen Sàrl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| BR112015021965B1 (pt) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos |
| NZ712035A (en) | 2013-03-13 | 2019-06-28 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| MX363787B (es) | 2013-03-13 | 2019-04-03 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de los mismos. |
| ES2749746T3 (es) | 2013-04-10 | 2020-03-23 | Syndevrx Inc | Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| CN116987193A (zh) | 2013-12-25 | 2023-11-03 | 第一三共株式会社 | 抗trop2抗体－药物偶联物 |
| EP3973995A1 (en) | 2014-01-31 | 2022-03-30 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| WO2015153401A1 (en) | 2014-04-04 | 2015-10-08 | Merck Sharp & Dohme Corp | Phosphate based linkers for intracellular delivery of drug conjugates |
| PL3129063T3 (pl) | 2014-04-10 | 2021-07-12 | Daiichi Sankyo Company, Limited | Koniugat lek-przeciwciało anty-her3 |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| CN108260357A (zh) | 2015-04-10 | 2018-07-06 | 托马斯杰弗逊大学 | 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物 |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US10800826B2 (en) | 2015-10-05 | 2020-10-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| EP3359194A4 (en) | 2015-10-06 | 2019-04-24 | Merck Sharp & Dohme Corp. | ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS |
| WO2017100553A1 (en) | 2015-12-10 | 2017-06-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CA3008960A1 (en) | 2016-01-11 | 2017-07-20 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| US10869929B2 (en) | 2016-01-29 | 2020-12-22 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| DK3544636T3 (da) | 2017-02-08 | 2021-05-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepin-antistof-konjugater |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| JP2020517609A (ja) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | ピロロベンゾジアゼピン複合体 |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| TW202530218A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| PT3668874T (pt) | 2017-08-18 | 2022-02-24 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| KR102816741B1 (ko) | 2017-08-31 | 2025-06-04 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
| CA3082310A1 (en) | 2017-11-29 | 2019-06-06 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| FI3794042T3 (fi) | 2018-05-18 | 2024-05-31 | Daiichi Sankyo Co Ltd | Anti-muc1-eksatekaani-vasta-aine-lääkekonjugaatti |
| CN112739340B (zh) | 2018-07-23 | 2025-05-13 | 海德堡医药研究有限责任公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| CN112533958B (zh) | 2018-07-27 | 2024-11-15 | 第一三共株式会社 | 识别抗体-药物缀合物的药物部分的蛋白 |
| KR20210038625A (ko) | 2018-07-31 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 |
| WO2020087077A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx,Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| US20200407440A1 (en) | 2019-04-24 | 2020-12-31 | Magenta Therapeutics, Inc. | Amatoxin antibody-drug conjugates and uses thereof |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CN110339181A (zh) * | 2019-07-02 | 2019-10-18 | 中国药科大学 | 一种基于点击反应的pH响应型纳米制剂及其制法和应用 |
| PE20220485A1 (es) | 2019-07-10 | 2022-04-04 | Cybrexa 3 Inc | Conjugados peptidicos de agentes dirigidos a microtubulos como terapeuticos |
| AU2020309570A1 (en) | 2019-07-10 | 2022-02-03 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| JP7682553B2 (ja) * | 2020-01-31 | 2025-05-26 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
| WO2022043256A1 (en) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Synergistic combinations of anticancer drugs linked to a tetrapeptidic moiety and immunotherapeutic agents |
| AU2021354823A1 (en) * | 2020-09-30 | 2023-03-30 | Duality Biologics (Suzhou) Co., Ltd. | Antitumor compound, and preparation method therefor and use thereof |
| JP2024501121A (ja) | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
| EP4267188A1 (en) | 2020-12-22 | 2023-11-01 | Cobiores NV | Compounds comprising a tetrapeptidic moiety |
| WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US20230355792A1 (en) | 2022-04-07 | 2023-11-09 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index |
| US20250297004A1 (en) | 2022-05-25 | 2025-09-25 | Innate Pharma | Nectin-4 binding agents |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992014759A1 (fr) | 1991-02-21 | 1992-09-03 | Drug Delivery System Institute, Ltd. | Carboxymethylmannoglucane et derive |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| DE69425464T2 (de) * | 1993-02-26 | 2001-05-23 | Drug Delivery System Institute, Ltd. | Polysaccharidderivat und wirkstoffträger |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH0784481A (ja) | 1993-06-26 | 1995-03-31 | Ricoh Co Ltd | 画像形成装置 |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) * | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| US6368598B1 (en) * | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| EP0941120A4 (en) * | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
| JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JPH1192405A (ja) * | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
| EP1619210A1 (en) * | 1998-10-30 | 2006-01-25 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
-
1999
- 1999-05-21 AU AU37333/99A patent/AU3733399A/en not_active Abandoned
- 1999-05-21 US US09/674,526 patent/US6835807B1/en not_active Expired - Fee Related
- 1999-05-21 EA EA200001217A patent/EA003398B1/ru not_active IP Right Cessation
- 1999-05-21 KR KR1020007013102A patent/KR100581443B1/ko not_active Expired - Fee Related
- 1999-05-21 WO PCT/JP1999/002681 patent/WO1999061061A1/ja not_active Ceased
- 1999-05-21 JP JP2000550520A patent/JP4560210B2/ja not_active Expired - Fee Related
- 1999-05-21 HK HK02101369.9A patent/HK1040052B/zh not_active IP Right Cessation
- 1999-05-21 CN CNB998089796A patent/CN1250293C/zh not_active Expired - Fee Related
- 1999-05-21 CA CA002333321A patent/CA2333321A1/en not_active Abandoned
- 1999-05-21 TW TW088108351A patent/TWI253935B/zh not_active IP Right Cessation
- 1999-05-21 EP EP99919664A patent/EP1080732A4/en not_active Withdrawn
-
2000
- 2000-11-22 NO NO20005913A patent/NO20005913L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1080732A4 (en) | 2004-08-25 |
| KR100581443B1 (ko) | 2006-05-23 |
| AU3733399A (en) | 1999-12-13 |
| WO1999061061A1 (fr) | 1999-12-02 |
| HK1040052A1 (en) | 2002-05-24 |
| CN1250293C (zh) | 2006-04-12 |
| HK1040052B (zh) | 2006-09-15 |
| TWI253935B (en) | 2006-05-01 |
| EA003398B1 (ru) | 2003-04-24 |
| CN1310631A (zh) | 2001-08-29 |
| EP1080732A1 (en) | 2001-03-07 |
| CA2333321A1 (en) | 1999-12-02 |
| JP4560210B2 (ja) | 2010-10-13 |
| EA200001217A1 (ru) | 2001-06-25 |
| NO20005913L (no) | 2001-01-22 |
| US6835807B1 (en) | 2004-12-28 |
| KR20010052385A (ko) | 2001-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20005913D0 (no) | Legemiddelsammensetning | |
| ID27415A (id) | Komposisi farmaseutik | |
| IS5046A (is) | Lyfjasamsetningar | |
| ID26186A (id) | Komposisi sampo | |
| ID28694A (id) | Komposisi sampo | |
| ID26720A (id) | Komposisi oral | |
| ID29430A (id) | Komposisi herbisida | |
| ID29262A (id) | Komposisi farmasi | |
| ID20233A (id) | Komposisi oral | |
| NO20004758D0 (no) | Vaksinesammensetning | |
| NO992692L (no) | Nefadozon doseringsform | |
| ID27201A (id) | Komposisi farmasi | |
| DK1466615T3 (da) | Farmaceutisk præparat | |
| DE69928862D1 (de) | Zusammensetzung | |
| DE69942892D1 (de) | Gaserzeugende zusammensetzung | |
| DK1023035T3 (da) | Mundplejemiddel | |
| ID20466A (id) | Komposisi oral | |
| ID29294A (id) | Komposisi farmasi | |
| ID25857A (id) | Komposisi farmasi | |
| EP1124557A4 (en) | Pharmaceutical composition | |
| ID26295A (id) | Komposisi keras-ultraviolet | |
| ID26215A (id) | Komposisi farmasi | |
| ID26485A (id) | Komposisi paroksetina | |
| FI961364L (fi) | Lääkeainekoostumus | |
| ID28359A (id) | Komposisi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |